Curcumin analog B inhibits cell proliferation and induces cell death in glioblastoma at lower concentrations than curcumin

DOI Web Site Open Access
  • Kyoko Inai
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Hamabe-Horiike Toshihide
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, National Hospital Organization Kyoto Medical Center Shizuoka General Hospital
  • Ono Masaya
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Iwashimizu Sonoka
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Ito Ryo
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka
  • Sunagawa Yoichi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, National Hospital Organization Kyoto Medical Center Shizuoka General Hospital
  • Katanasaka Yasufumi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, National Hospital Organization Kyoto Medical Center Shizuoka General Hospital
  • Arakawa Yoshiki
    Department of Neurosurgery, Kyoto University Graduate School of Medicine
  • Philip Hawke
    Laboratory of Scientific English, School of Pharmaceutical Sciences, University of Shizuoka
  • Hasegawa Koji
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, National Hospital Organization Kyoto Medical Center
  • Morimoto Tatsuya
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, National Hospital Organization Kyoto Medical Center Shizuoka General Hospital

Bibliographic Information

Other Title
  • Curcumin誘導体Compound BはCurcuminより低濃度で膠芽腫の細胞増殖を抑制し、細胞死を誘導した

Description

<p>PURPOSE: Glioblastoma (GBM) has a high risk of recurrence and a poor prognosis due to the difficulty of surgical resection and resistance to the standard pharmacological treatment, temozolomide. Therefore, the development of new therapeutic agents against GBM is needed. This study investigated the anti-tumor activity of the curcumin (Cur) analog Compound B (ComB) against GBM. </p><p>METHODS AND RESULTS: To evaluate anti-tumor activity against GBM, an MTT assay was performed. The human GBM cell lines U87-MG and U251 were pre-treated with Cur or ComB, then cell viability was examined using a cell counting kit, and IC50 values were calculated. For U87-MG, the IC50 values for Cur and ComB were 9.78 and 1.28 µM, respectively; for U251, they were 9.50 and 0.64 µM, respectively. To examine the effects of ComB on normal cells, the same MTT assay was performed on primary cultured astrocytes from neonatal rats. ComB did not reduce cell viability in astrocytes at concentrations that had an anti-tumor effect on GBM cells (1.5 µM). Next, a cell cycle analysis was performed with PI staining and an apoptosis assay with annexin V/PI staining using flow cytometry. ComB induced G2/M phase arrest and apoptosis at lower concentrations than Cur. </p><p>DISCUSSION: These results suggest that ComB, at lower concentrations than Cur, has an anti-tumor effect without affecting normal cells by inducing cell cycle arrest and apoptosis against GBM. Further detailed analysis and in vivo studies of ComB may lead to the development of novel therapeutic agents for GBM.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top